On October 6, 2026, BioLife Solutions, Inc. completed its acquisition by Repligen Corporation. The deal was executed through a two-step merger process involving Merger Sub 1 and Merger Sub 2, resulting in BioLife ceasing to exist as a separate legal entity and becoming a wholly owned subsidiary of Repligen.
Under the terms of the Agreement and Plan of Merger, dated July 21, 2026, BioLife stockholders received a combination of cash and Repligen common stock. Each share of BioLife common stock, par value $0.001, issued and outstanding prior to the effective time of the First Merger converted into the right to receive (A) 0.1442 shares of Repligen common stock and (B) $11.25 in cash. The company also confirmed that no fractional shares of Repligen common stock were issued, with cash provided in lieu of any fractional shares.
BioLife’s board of directors and named executive officers resigned effective at the First Merger Effective Time. Roderick de Greef, Cathy Coste, Amy DuRoss, Rachel Ellingson, Joydeep Goswami, MBA, PhD, Tony Hunt, and Tim Moore stepped down from the board, while Roderick de Greef, Troy Wichterman, Aby J. Mathew, Todd Berard, and Sean Warner resigned from their officer positions.
Following the completion of the mergers, BioLife notified Nasdaq that it no longer meets listing requirements. The company requested that trading of its common stock be halted and intends to file a Certification and Notice of Termination of Registration on Form 15 to deregister its shares and cease its reporting obligations under the Securities Exchange Act.
